Abstract
Caris Life Sciences reported at the American Society of Hematology (ASH) Annual Meeting & Exposition in December that it has identified a new mechanism of action for an aptamer with potential to treat non-Hodgkin lymphoma (NHL), using the company's proprietary ADAPT Biotargeting System.
In it research, Caris scientists reported that the single-stranded DNA aptamer C10.36 specifically binds to heterogeneous nuclear ribonucleoprotein U (hnRNP U), a protein that controls pre-mRNA splicing.
“The present study identifies cell surface hnRNP U and its ribonucleoprotein interaction partners as potential therapeutic targets for NHL and highlights the potential for the development of C10.36 as a novel anti-B cell lymphoma targeted therapy,” researchers from Caris and the University of Bonn, led by Caris' Sonal S. Tonapi, Ph.D., concluded in the study.
Study results also showed that C10.36 binding to cell-surface hnRNP U resulted in internalization of the complex, disruption of pre-mRNA splicing and cell death in a subset of NHL cell lines in vitro. The authors concluded that the aptamer binds to hnRNP U and kills NHL cells via a novel mechanism of interfering with pre-mRNA splicing.
PASIEKA / Getty Images
